Additionally, future work will use SPOKE to identify people that can undergo more intensive evaluation to estimate PD risk using clinical and biomarker assessments, such as smell test or imaging of striatal dopamine transporter binding (37). The gene discussed is SLC6A3; the disease is Parkinson disease.